Lexicon Pharmaceuticals AI Stock Analysis
Want to see LXRX full AI Analyst Report?
Lexicon Pharmaceuticals (LXRX) AI Stock Analysis
Lexicon Pharmaceuticals
(NASDAQ:LXRX)
LXRX scores below average primarily due to weak financial performance (ongoing large losses and cash burn despite a debt-free balance sheet) and only modest technical strength (below key longer-term moving averages with negative MACD). The earnings call improves the outlook with clear near-term clinical/regulatory catalysts and maintained expense guidance, but valuation remains constrained by lack of profitability and no dividend support.
Lexicon Pharmaceuticals (LXRX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $779.16M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.60M
- Price to Earnings (P/E)
- -12.0
- Beta (1Y)
- 1.45
- Revenue Growth
- -45.62%
- EPS Growth
- 21.16%
- Country
- US
- Employees
- 81
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Lexicon Pharmaceuticals Business Overview & Revenue Model
Company Description
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug...
How the Company Makes Money
Lexicon Pharmaceuticals makes money primarily through a combination of (1) collaboration and licensing arrangements and (2) any product-related revenue from commercialized drugs, if applicable, along with (3) other operating income sources typical fo...
Lexicon Pharmaceuticals Earnings Call Summary
The call was predominantly positive, with management highlighting completed SONATA-HCM enrollment, encouraging STENO1 safety data, the planned ZYNQUISTA NDA resubmission, regulatory progress through Viatris, a $10 million LX9851 milestone, promising pilavapadin weight-loss data, and a higher cash balance. The principal negatives were lower year-over-year revenue, a larger net loss, higher SG&A expenses, and delays and administrative complexity surrounding the ZYNQUISTA resubmission. Multiple significant clinical and regulatory catalysts expected in the first quarter of 2027 supported an overall favorable tone.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Lexicon maintained its 2026 operating expense guidance of between $100 million and $110 million, with R&D expected to be between $63 million and $68 million and SG&A expected to be between $37 million and $42 million; the company expects SONATA-HCM top-line results in the first quarter of 2027, expects to complete the ZYNQUISTA NDA resubmission in the first quarter of 2027, expects SOTA-CROSS completion in 2027, and expects additional milestone payments as LX9851 advances.
Lexicon Pharmaceuticals Financial Statement Overview
Summary
Financial fundamentals are weak overall: revenue declined (~7% TTM) and the company remains deeply unprofitable (EBIT -$56.8M; net loss -$62.4M; net margin ~-162%) with ongoing cash burn (TTM FCF -$49.2M). The key offset is a healthier balance sheet with $0 debt and meaningful equity, plus improving losses versus 2024, but profitability and self-funding are still not in place.
Income Statement
24NegativeBalance Sheet
62PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.54M | 49.80M | 31.08M | 1.20M | 139.00K | 298.00K |
| Gross Profit | 37.99M | 49.53M | 30.46M | -57.77M | -52.38M | -54.75M |
| EBITDA | -56.19M | -41.38M | -184.29M | -169.76M | -100.03M | -86.66M |
| Net Income | -62.35M | -50.34M | -200.40M | -177.12M | -101.94M | -87.76M |
Balance Sheet | ||||||
| Total Assets | 242.02M | 184.99M | 298.42M | 229.43M | 194.30M | 136.91M |
| Cash, Cash Equivalents and Short-Term Investments | 183.20M | 96.23M | 237.96M | 170.03M | 138.36M | 86.74M |
| Total Debt | 59.54M | 62.24M | 108.40M | 106.06M | 55.29M | 2.28M |
| Total Liabilities | 78.18M | 77.45M | 152.47M | 136.32M | 77.17M | 23.31M |
| Stockholders Equity | 163.84M | 107.54M | 145.95M | 93.11M | 117.12M | 113.59M |
Cash Flow | ||||||
| Free Cash Flow | -63.96M | -67.85M | -179.81M | -162.37M | -90.18M | -88.24M |
| Operating Cash Flow | -63.96M | -67.85M | -178.78M | -161.90M | -88.85M | -87.02M |
| Investing Cash Flow | -140.98M | 113.02M | -15.38M | -49.94M | -71.08M | 2.11M |
| Financing Cash Flow | 174.13M | -48.50M | 238.35M | 187.96M | 142.21M | 22.71M |
Lexicon Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXRX, the sentiment is Neutral. The current price of 1.75 is above the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.76, and below the 200-day MA of 1.90, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.71 is Neutral, neither overbought nor oversold. The STOCH value of 65.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LXRX.
Lexicon Pharmaceuticals Risk Analysis
Lexicon Pharmaceuticals disclosed 38 risk factors in its most recent earnings report. Lexicon Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksLexicon Pharmaceuticals Peers Comparison
Overall Rating
RIGL79Outperform
INVA61Neutral
MNKD55Neutral
ARDX49Neutral
LXRX49Neutral
VNDA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | $823.43M | 2.58 | 73.94% | ― | 2.18% | 165.65% | |
| 61Neutral | $1.31B | 7.31 | 15.84% | ― | 12.38% | 34.41% | |
| 55Neutral | $1.27B | -16.75 | 139.41% | ― | 31.74% | -344.30% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $771.71M | -13.56 | -35.30% | ― | 17.57% | 4.82% | |
| 49Neutral | $779.16M | -12.01 | -38.44% | ― | -45.62% | 21.16% | |
| 39Underperform | $230.39M | -0.82 | -106.94% | ― | 8.11% | -222.50% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LXRX | Lexicon Pharmaceuticals | 1.75 | 0.30 | 20.69% | |
| MNKD | MannKind Corporation | 3.96 | -1.04 | -20.90% | |
| RIGL | Rigel Pharmaceuticals | 43.73 | 2.05 | 4.92% | |
| INVA | Innoviva | 18.49 | -2.78 | -13.07% | |
| VNDA | Vanda Pharmaceuticals | 3.81 | -1.33 | -25.88% | |
| ARDX | Ardelyx Inc | 3.07 | -2.50 | -44.88% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
